|
|||||
|
|
Eli Lilly and Co. is licensing a a treatment candidate for Alzheimer’s disease from biopharmaceutical company AC Immune that aims to block accumulation of tau proteins in the brain. . . . → Read More: Lilly, Biopharm Partner on Alzheimer’s Treatment in $2B Deal  Comments are closed  Intellectual property, Joint ventures/collaborations  biomedical, clinical trials, equity, Europe, investment, licensing, life sciences, pharmaceuticals 
Techniques for delivering drugs in capsule form that last a week or longer in the patient are expected to receive a patent soon from U.S. authorities. . . . → Read More: Patent Set for Long-Term Drug Capsules 2 comments - (Comments are closed) Intellectual property, New products biomedical, engineering, entrepreneurs, HIV, licensing, life sciences, materials science, patent, pharmaceuticals, physical sciences, university, USPTO 
An affiliate of drug maker Janssen Pharmaceutical is licensing a synthetic antibody to treat blood-related cancers from a developer of antibodies based on the immune system of llamas. . . . → Read More: Janssen Licensing Cancer Antibodies in $1.8B Deal Comments are closed Finance, Intellectual property biomedical, biotechnology, cancer, clinical trials, equity, Europe, investment, licensing, life sciences, pharmaceuticals, stem cells 
Dicerna Pharmaceuticals, developing treatments for disease that silence genes by interfering with their RNA instructions, is licensing its technology to drug maker Eli Lilly and Co . . . → Read More: Gene Silencing Technology Licensed in $3.7B Deal Comments are closed Intellectual property, Joint ventures/collaborations biomedical, biotechnology, equity, genomics, investment, licensing, life sciences, pharmaceuticals 
The global chemical company BASF is licensing a more precise form of genome editing from the Broad Institute, a genetics research center affiliated with Harvard University and MIT. . . . → Read More: BASF Licensing Precise Crispr Editing from Broad Institute One comment - (Comments are closed) Intellectual property agriculture, biomedical, biotechnology, chemistry, Europe, genomics, licensing, manufacturing, patent, physical sciences, university 
A company in Maryland developing alternatives to human organ transplants is licensing a technology to help create 3-D printed lungs for transplantation with bioinks derived from tobacco plants. . . . → Read More: Licensing Deal for Bioinks in 3-D Printed Transplant Lungs One comment - (Comments are closed) Intellectual property, New products agriculture, biomedical, biotechnology, engineering, entrepreneurs, Israel, licensing, life sciences, materials science, medical device, physical sciences, university 
Drug maker AbbVie and biotechnology company Morphic Therapeutic are collaborating on new treatments for fibrosis based on Morphic’s technology blocking proteins that promote fibrosis. . . . → Read More: Harvard Spin-Off, AbbVie Partner on Fibrosis Treatments One comment - (Comments are closed) Intellectual property, New products biomedical, biotechnology, licensing, life sciences, pharmaceuticals, preclinical, university 
A document with standard legal language for terms and conditions of sharing biotechnology materials is now available for academic and industry research labs. . . . → Read More: Model Biotech Materials Sharing Agreement Unveiled Comments are closed Intellectual property, Joint ventures/collaborations biomedical, biotechnology, life sciences, NIH, standard, U.K., university 
A start-up enterprise founded by medical researchers in the U.S. and Europe is developing treatments for cancer and autoimmune disorders that change chemical reactions in immune system cells. . . . → Read More: Start-Up Developing Immunometabolism Therapies, Gains $30M Funding Comments are closed Finance, Intellectual property biomedical, biotechnology, cancer, chemistry, entrepreneurs, equity, Europe, investment, licensing, life sciences, pharmaceuticals, physical sciences, university, venture capital 
A biotechnology company developing therapies that silence the actions of disease-causing genes is licensing its treatment program for hepatitis-B to Janssen Pharmaceuticals. . . . → Read More: Biotech in $3.7B Licensing Deal for Hepatitis-B One comment - (Comments are closed) Finance, Intellectual property biomedical, biotechnology, clinical trials, equity, genomics, investment, licensing, life sciences, pharmaceuticals |
||||
|
Copyright © 2019 Technology News and Literature - All Rights Reserved Powered by WordPress & Atahualpa |
|||||
